{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:54:13Z","timestamp":1791104053234,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2010,9,21]],"date-time":"2010-09-21T00:00:00Z","timestamp":1285027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2011,5]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>Study Type \u2013 Therapy (RCT) \u2028Level of Evidence\u20031b<\/jats:p>\n                    <jats:p>\n                      <jats:bold>What\u2019s known on the subject? and What does the study add?<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>A previous trial found greater efficacy with the maximum available dose of fesoterodine 8 mg compared with the maximum available dose of tolterodine ER 4 mg and placebo for improving overactive bladder symptoms, and patient\u2010reported outcomes were demonstrated by a recent placebo\u2010controlled, head\u2010to\u2010head trial.<\/jats:p>\n                    <jats:p>The results of this trial, the largest to date to compare antimuscarinic efficacy, confirms the superior efficacy of fesoterodine 8 mg over tolterodine ER 4 mg for the treatment of OAB symptoms, and further emphasize the clinical advantage of the availability of an additional 8\u2010mg dose over single\u2010dose tolterodine ER 4 mg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>\u2022\u2002To show the superior efficacy of fesoterodine over tolterodine extended release (ER) in a placebo\u2010controlled overactive bladder (OAB) trial with predefined treatment comparisons for both diary measures and patient\u2010reported outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>\u2022\u2002In this 12\u2010week, double\u2010blind, double\u2010dummy trial, subjects reporting &gt;1 urgency urinary incontinence (UUI) episode and \u22658 micturitions per 24\u00a0h at baseline were randomized to fesoterodine (4\u00a0mg for 1 week, 8\u00a0mg for 11 weeks), tolterodine ER 4\u00a0mg, or placebo.<\/jats:p>\n                    <jats:p>\u2022\u2002Subjects completed 3\u2010day bladder diaries, the Patient Perception of Bladder Condition (PPBC) and the Urgency Perception Scale (UPS) at baseline and weeks 1, 4 and 12 and the OAB Questionnaire at baseline and week 12.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      \u2022\u2002A total of 2417 subjects were randomized. At week 12, fesoterodine 8\u00a0mg showed superiority over tolterodine ER 4\u00a0mg and placebo on UUI episodes (primary endpoint), micturitions, urgency and most other diary endpoints, and on the PPBC, UPS and all OAB Questionnaire scales and domains (all\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05).\n                    <\/jats:p>\n                    <jats:p>\n                      \u2022\u2002Superiority of fesoterodine 8\u00a0mg over tolterodine ER 4\u00a0mg was seen as early as week 4 (3 weeks after escalation to fesoterodine 8\u00a0mg). At week 1, fesoterodine 4\u00a0mg was superior to placebo on most diary variables, the PPBC and the UPS (all\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05). Dry mouth and constipation rates were 28% and 4% with fesoterodine, 13% and 3% with tolterodine ER, and 5% and 2% with placebo.\n                    <\/jats:p>\n                    <jats:p>\u2022\u2002Discontinuation rates as a result of adverse events were 5%, 3% and 2% for fesoterodine, tolterodine ER and placebo, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>\u2022\u2002In this randomized study, which is the largest to compare antimuscarinic efficacy performed to date, fesoterodine 8\u00a0mg was superior to tolterodine ER 4\u00a0mg for UUI episodes, micturitions and urgency episodes, as well as for self\u2010reported patient assessments of bladder\u2010related problems, urgency, symptom bother and health\u2010related quality of life.<\/jats:p>\n                    <jats:p>\u2022\u2002The superiority of fesoterodine 8\u00a0mg over tolterodine ER 4\u00a0mg was observed as early as 3 weeks after escalation from fesoterodine 4\u00a0mg for most outcomes. These data may have important implications for the clinical management of OAB patients previously treated with tolterodine ER.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2010.09640.x","type":"journal-article","created":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T08:54:42Z","timestamp":1285750482000},"page":"1432-1440","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head\u2010to\u2010head, placebo\u2010controlled trial"],"prefix":"10.1111","volume":"107","author":[{"given":"Steven A.","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenelle E.","family":"Foote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghong","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,9,21]]},"reference":[{"key":"e_1_2_8_2_2","volume-title":"Initial National Priorities for Comparative Effectiveness Research","author":"Prioritization CoCER","year":"2009"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.4065\/78.6.687"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)62382-3"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.05.015"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(03)00356-X"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2003.04468.x"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.07031.x"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.04.023"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.09086.x"},{"key":"e_1_2_8_11_2","unstructured":"ICH Expert Working Group.Statistical principles for clinical trials E9.International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.1998"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.10.1787"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90104-7"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.5414\/CPP46556"},{"key":"e_1_2_8_15_2","volume-title":"Full Prescribing Information","author":"Detrol\u00ae LA (tolterodine tartrate)","year":"2008"},{"key":"e_1_2_8_16_2","volume-title":"Full Prescribing Information","author":"Toviaz\u00ae (fesoterodine fumarate)","year":"2008"},{"key":"e_1_2_8_17_2","unstructured":"European Medicines Agency (EMEA).EPARs for authorized medicinal products for human use. European Public Assessment Report for Toviaz (Product Information). Updated August 2009. Available at:http:\/\/www.emea.europa.eu\/humandocs\/Humans\/EPAR\/toviaz\/toviaz.htm. Accessed 20 October 2009"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.07.009"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07907.x"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.05.042"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.01.007"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05345.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016370925601"},{"key":"e_1_2_8_24_2","volume-title":"Statistics for Experimenters","author":"Box GEP","year":"1978"},{"key":"e_1_2_8_25_2","first-page":"351","article-title":"On the combination of independent two\u2010sample tests of Wilcoxon","volume":"37","author":"Van Elteren PH","year":"1960","journal-title":"Bull Int Stat Inst"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07601.x"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802537122"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)85137-2"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000127742.73136.0c"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07939.x"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2010.09640.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2010.09640.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T10:21:55Z","timestamp":1761733315000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2010.09640.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,21]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["10.1111\/j.1464-410X.2010.09640.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2010.09640.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,21]]},"assertion":[{"value":"2010-09-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}